ENSC — Ensysce Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $6.09m
- $2.96m
- $5.21m
- 44
- 41
- 16
- 25
Annual cashflow statement for Ensysce Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 4.31 | -29.1 | -24.2 | -10.6 | -7.99 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -5.92 | 21.9 | 0.778 | 0.775 | 1.29 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.749 | -0.954 | 5.54 | -0.928 | -0.807 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.864 | -8.24 | -17.9 | -10.8 | -7.5 |
| Other Investing Cash Flow Items | 183 | — | 0.004 | 0 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Cash from Investing Activities | 183 | — | 0.004 | 0 | — |
| Financing Cash Flow Items | — | -0.489 | -1.14 | -0.9 | -1.84 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -184 | 20.3 | 8.77 | 8.76 | 9.88 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.01 | 12.1 | -9.12 | -2.02 | 2.38 |